-
Hard Copy
-
CD ROM
-
Electronic (PDF)
-
Enterprisewide
US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer with Increased PSA and Adenocarcinoma
The Assessment Group, March 2011, Pages: 35
Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.
This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer.
Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists' decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
- Understand what occurs with actual patients
- Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies
- Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget
- Understand where your product fits
- Understand where your competitor's product fits
- Design messages to advance brand performance
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Advanced Prostate Cancer
Chapter 2: Respondent Demographics
Table 2.1 Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by States
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of a patient with increased PSA and adenocarcinoma
Figure 3.1 Next step in a patient with increased PSA and adenocarcinoma
Figure 3.2 Tests to be performed at this time with the patient
Figure 3.3 Confidence in treating to optimal outcome
Figure 3.4 Treatment decision with disease progression
Figure 3.5 Treatment decision with disease progression
Figure 3.6 Factors that influenced treatment
Chapter 4: Summary
Appendix A: Survey Instrument
- Novartis
- Astra Zeneca
- Merck
- Ferring
- Abbott Laboratories
- TEVA
- Eli Lilly
- Genentech/Roche
- Bristol-Myers Squibb
- Pfizer
- Sanofi-aventis
- Centocor/Ortho Biotech
- EMD Serono
- Dendreon
- Celegene
- Watson
- Amgen
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
